A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

854

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Standard of Care
DRUG: Telisotuzumab Adizutecan
DRUG: Osimertinib (Osi)
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

AbbVie